Navigation Links
NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
Date:7/9/2014

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. CRS3123 (previously known as REP3123) is a narrow-spectrum agent that inhibits C. difficile growth while sparing normal intestinal bacteria.

The Phase I trial will enroll up to 30 healthy men and women ages 18 to 45 in a dose-escalation study to evaluate the investigational drug's safety and tolerability. Quintiles, through Dynport Vaccine Company, is conducting the study of CRS3123. The medication is being provided by its developer, Crestone, Inc., a pharmaceutical company based in Boulder, Colo.

C. difficile infection affects the digestive track with manifestations ranging from mild diarrhea to life-threatening colitis. Infection most commonly affects patients in hospitals or long-term care facilities and people who have taken antibiotics. Each year, roughly 250,000 people in the United States require hospital care for C. difficile infection and at least 14,000 people die from the infection, according to the U.S. Centers for Disease Control and Prevention (CDC). As a result, the CDC identified C. difficile as an urgent public health threat in its 2013 report on antibiotic resistance. Resistance to the antibiotics currently used to treat C. difficile is not yet a problem, but the bacteria spreads rapidly because it is naturally resistant to many drugs used to treat other infections. Recurrent infections pose a particular clinical challenge, especially those caused by a newer, stronger C. difficile strain, which result in up to 25 percent of patients needing additional therapy.

In the new clinical trial, participants will be randomly assigned into three groups of 10 participants each (8 participants will receive the investigational drug; 2 participants will receive a placebo pill). In the first group, participants will receive either 200 milligrams (mg) of CRS3123 or placebo twice daily for 10 days. Based on the review of safety data from this group, the study will progress to a second and then a third group of volunteers with a maximum possible dose of 600 mg twice daily. Participation in the trial will require an inpatient stay of 12 days to allow for monitored dosing and physical evaluations, including blood tests and urinalysis. Participants will be evaluated on an outpatient basis 18 and 29 days after receiving the first dose of the investigational drug. The study is expected to be completed by March 2015.


'/>"/>
Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert  

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. Mayo Clinic launches whole genome breast cancer study
3. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
4. UCLA launches first face transplantation program in western US
5. Georgia Tech launches HomeLab to help companies evaluate home health technologies
6. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
7. K9 CarFence™ Launches as Newest Innovation in Pet Transportation
8. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
9. 'Music Makes It Better' Campaign Launches with Justin Bieber, Victoria Justice, and The Band Perry
10. Fieldtex Products Launches a New Wellness Rewards Service for Companies
11. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, ... biologics, consumer health and global clinical supply services, today announced two key appointments ... company’s continued investment and strategic growth plans in the Asia Pacific region. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life ... announced the organization has earned its ISO 13485 certification, indicating the company’s quality ... all rules and policies associated with ISO quality standard 13485. , BSI ...
(Date:5/26/2016)... York, NY (PRWEB) , ... May 26, 2016 ... ... researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon International ... Disease and Regeneration. The conference was held during May 5-6, 2016 in Chicago, ...
(Date:5/26/2016)... ... May 26, 2016 , ... OncLive® , ... National Cancer Institute-designated University of Virginia (UVA) Cancer Center to its ... editorial and marketing teams will publicize and promote public awareness of UVA Cancer ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... 20 years of experience in leading technology and human resources operations for health ... teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25, 2016 Digital Health Dialog, LLC ... by the US Patent and Trademark Office of ... proprietary processes for electronic opt-­in and processing of ... programs, HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to ...
(Date:5/24/2016)... 24, 2016 Niederländische Chirurgen ... die es Ärzten erlaubt, ihre Expertise weltweit zu ... kombiniert Live Streaming mit einer Instant-Messaging-Funktion und der ... Mediziner in Europa, Afrika, Asien und den ... die Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
Breaking Medicine Technology: